Americas Influencing Transdermal Drug Delivery Systems Market


Introduction to TDDS:
The human skin is the largest organ of the human body. The skin covers a surface of nearly two square meters and receives nearly one-third of the blood in the body. Delivering drugs to the body through the skin has proved to be one of the most effective means of drug delivery besides oral delivery of drugs and therefore has received greater attention from the pharmaceutical industry due to increasing demand for controlled drug delivery. Skin is one of the most readily accessible organs of the human body. There is considerable interest in the skin as a site of drug application both for local and systemic effect, a factor that has added considerable interest to the transdermal drug delivery systems market.
The global Transdermal Drug Delivery Systems Market is expected to register a healthy CAGR over the forecast period. The market held a market value of USD 5,400.2 Million in 2017 and is projected to grow at a CAGR of 4.6% during the forecast period from 2018 to 2023.
Furthermore, the increasing occurrence of needle-stick injuries and growing uses of biologics are driving market growth. Substantial investments drawn in the R&D to develop advanced TDD systems are boosting the growth of the market, significantly. Additionally, spreading awareness, improving outcomes & patients’ experience, and beneficial reimbursement policies impact the market growth, positively for the transdermal drug delivery systems market which amassed nearly USD 5,400.2 million in 2017.
Benefits of TDDS:
The transdermal drug delivery systems market has been expanding due to various advantages of transdermal delivery circumventing the liver which can often prematurely metabolize drugs. Unlike hypodermic injections, transdermal deliveries are not painful, do not generate dangerous medical waste and are great for avoiding the risk of disease transmission by needle re-use which often a considerable risk factor in countries with impoverished healthcare facilities. Transdermal systems are non-invasive and can be self-administered, can provide release for long periods and have been known to improve patient compliance being generally inexpensive.
The limited number of drug available that can be transdermally administered is possibly one of the greatest challenges for the transdermal drug delivery systems market. This is because current delivery methods can only enable transdermal drugs that have molecular masses only up to a few hundred Daltons and require doses of milligrams per day or less. Therefore, transdermal delivery of peptides and macromolecules, hydrophilic drugs and novel genetic treatment that employ the use of DNA or small-interfering RNA are yet to be delivered through transdermal methods. Increasing investment in the transdermal drug delivery systems industry and tireless R&D that are aimed at enhancement of the
Regional Analysis:
North America dominates the global transdermal (percutaneous) drug delivery systems market with the largest market share. Factors such as the presence of major market players and developed healthcare infrastructure drive the growth of the regional market. Moreover, surging numbers of research activities related to transdermal drug delivery systems and comparatively higher adoption of TDD systems in the US and Canada impact the regional market growth, positively.
Besides, the highest GDP helps North America to have the edge over other regions in terms of every aspect, including healthcare and technology. Additionally, huge patient pool suffering from chronic diseases such as cardiovascular diseases alongside the presence of geriatric population and development in medical technology is supporting the growth of the market. The US, backed by the high per capita healthcare expenditures, contributes to the growth of the regional market, significantly.
Europe takes the second-leading position in the global transdermal drug delivery systems market. The phenomenal growth in the pharmaceutical industry and the presence of pharma giant companies such as Novartis International AG, Mylan N.V., Boehringer Ingelheim International GmbH, and Allergan plc., bolster the regional market growth. The resurging economy is playing a vital role in market development, allowing the proliferation of the healthcare sector in the region.
Germany, heading with its flourishing medical devices markets, hugely contributes to the growth of the regional market. Furthermore, the UK and France with the increasing investment in transdermal drug delivery systems drive the regional market at a large scale. The Europe TDDS market is estimated to register a phenomenal CAGR during the review period.

Comments

Post a Comment

Popular posts from this blog

Gene Therapy Market Mobilizing Viral Vector Manufacturing Market

Market Overview: The global viral vector manufacturing market is expected to exhibit a strong 22.65% CAGR over the forecast period from 2018 to 2023 , according to the latest research report from Market Research Future (MRFR). The report forecasts a valuation of USD 319 million for the market by the end of the 2018-2023 forecast period. In current time, gene therapy is one of the preferred treatment options for most chronic diseases, that involves the insertion of a functional copy of a gene into a defective cell. viral vectors and the absence of the appropriate tools are likely to be the key restraints acting against the global Viral Vector Manufacturing Market Size over the forecast period. Many companies in the global viral vector manufacturing market are taking steps to counter the difficulties in producing viral vectors and this area is likely to remain a hive of activity in the coming years. This has also resulted in strong growth prospects for companies that can develop e...
Read more

Negative Pressure Wound Therapy Market is Increasing at a Healthy CAGR of 6.7% During Forecast to 2023

    MRFR Processed new research on “Negative Pressure Wound Therapy Market-Global Forecast to   Market Analysis:    The worldwide negative pressure wound therapy market is predicted to grow at a 6.7% CAGR during the forecast period (2018-2023), according to the latest Market Research Future (MRFR) report. Negative pressure wound therapy or NPWT, which is also called vacuum-assisted wound closure, includes the use of sub-atmospheric pressure for healing chronic and acute wounds. These devices come in assorted sizes and shapes to match the patient’s body contour and also the wound size to be treated. NPWT devices have a dressing set, drainage tubing, and vacuum pump that along with promoting wound healing also helps in reducing recurrent usage of dressings, offer an effective choice for managing closed surgical incision lines as well as augment the well-being of the patient.    Also Read: https://www.medgadget.com/2020/02/negative-pressur...
Read more

North Americas Uplifting 3D Printed Medical Implants Market

Market Overview: Expanding innovative advances in 3D printed implants, for example, improvement of CT-Bone, bone indistinguishable redid embed for use in mandible and zygoma increase procedure should help business development. Its controlled porosity empowers it to fit life structures of the patient, in this manner, dominatingly driving industry development. Also, increment in medicinal services consumption, ascend in R&D venture, flood in number of medical procedures and expanding extent of 3D innovation in biomedical application will spike income size during the figure time frame. In any case, factors, for example, significant expense of printers, longer creation courses of events, absence of talented representatives and absence of in-house added substance fabricating assets is relied upon to obstruct 3D printed implants market development over the coming years. The market for 3D Printed Medical Implants Market   is likely to register a CAGR of 18.1% during the foreca...
Read more